89bio logo
89bio ETNB

Quarterly report 2025-Q2
added 08-08-2025

report update icon

89bio Balance Sheet 2011-2026 | ETNB

Annual Balance Sheet 89bio

2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

-89.6 M -291 M -34.9 M -33 M -98.2 M -93.3 M -11.2 M - - - - - - -

Long Term Debt

35.7 M 24.8 M 20.2 M 16.9 M - - - - - - - - - -

Long Term Debt Current

727 K 496 K 168 K 2.5 M - - - - - - - - - -

Total Non Current Liabilities

- - - - - - 23.1 M - - - - - - -

Total Current Liabilities

36.1 M 29.6 M 24.6 M 19.5 M 8.11 M 5.61 M - - - - - - - -

Total Liabilities

77.9 M 60 M 45 M 36.5 M 8.11 M 5.61 M 27.4 M - - - - - - -

Retained Earnings

-825 M -457 M -315 M -213 M -123 M -73.6 M -16.2 M - - - - - - -

Total Assets

479 M 596 M 197 M 162 M 211 M 95.6 M 11.4 M - - - - - - -

Cash and Cash Equivalents

126 M 316 M 55.3 M 52.4 M 98.2 M 93.3 M 11.3 M - - - - - - -

Book Value

401 M 536 M 152 M 126 M 203 M 89.9 M -16.1 M - - - - - - -

Total Shareholders Equity

401 M 536 M 152 M 126 M 203 M 89.9 M -16.1 M - - - - - - -

All numbers in USD currency

Quarterly Balance Sheet 89bio

2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

36.2 M 35.9 M 35.7 M 35.5 M 20.4 M 23.1 M 24.8 M 24.6 M 24.5 M - 20.2 M 13 M 12 M 14.5 M 16.9 M 1.44 M 1.43 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

81.8 M 79.6 M 77.9 M 80.2 M 67.2 M 66.8 M 60 M 49.9 M 50.5 M - 45 M 48 M 67.4 M 33 M 36.5 M 21.3 M 9.01 M - 8.11 M 8.11 M 8.11 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

-1.01 B -896 M -825 M -706 M -557 M -509 M -457 M -417 M -382 M - -315 M -291 M -264 M -239 M -213 M -187 M -159 M -138 M -123 M -123 M -123 M -123 M -73.6 M -73.6 M -73.6 M -73.6 M -16.2 M -16.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

603 M 685 M 479 M 458 M 582 M 577 M 596 M 460 M 493 M - 197 M 201 M 148 M 136 M 162 M 168 M 182 M 199 M 211 M 211 M 211 M 211 M 95.6 M 95.6 M 95.6 M 95.6 M 11.4 M 11.4 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

129 M 315 M 126 M 91.4 M 212 M 218 M 316 M 252 M 245 M 351 M 55.3 M 72.4 M 60.6 M 54.9 M 52.4 M 39.7 M 35.7 M 68 M 98.2 M 98.2 M 98.2 M 98.2 M 93.3 M 93.3 M 93.3 M 93.3 M 11.2 M 11.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Book Value

522 M 605 M 401 M 378 M 515 M 511 M 536 M 410 M 442 M - 152 M 153 M 80.2 M 103 M 126 M 147 M 173 M 199 M 203 M 203 M 203 M 211 M 95.6 M 95.6 M 95.6 M 95.6 M 11.4 M 11.4 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

522 M 605 M 401 M 378 M 515 M 511 M 536 M 410 M 442 M 446 M 152 M 153 M 80.2 M 103 M 126 M 147 M 173 M 190 M 203 M 203 M 203 M 203 M 89.9 M 89.9 M 89.9 M 89.9 M -16.1 M -16.1 M -7.36 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in USD currency

Balance Sheet is a fundamental financial report of 89bio, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
AlloVir AlloVir
ALVR
- 4.14 % $ 49.1 M usaUSA
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
Ampio Pharmaceuticals Ampio Pharmaceuticals
AMPE
- -11.43 % $ 502 K usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Applied Therapeutics Applied Therapeutics
APLT
- - $ 8.42 M usaUSA
Aptorum Group Limited Aptorum Group Limited
APM
$ 0.88 -1.73 % $ 6.47 M chinaChina
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
ACADIA Pharmaceuticals ACADIA Pharmaceuticals
ACAD
$ 22.48 0.81 % $ 3.73 B usaUSA
Aptinyx Aptinyx
APTX
- -39.0 % $ 4.57 M usaUSA
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Ayala Pharmaceuticals Ayala Pharmaceuticals
AYLA
- - $ 7.46 M israelIsrael
Brainstorm Cell Therapeutics Brainstorm Cell Therapeutics
BCLI
- -2.5 % $ 5.88 M usaUSA
BioDelivery Sciences International BioDelivery Sciences International
BDSI
- -4.8 % $ 255 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Cara Therapeutics Cara Therapeutics
CARA
- -3.03 % $ 260 M usaUSA
CASI Pharmaceuticals CASI Pharmaceuticals
CASI
- - $ 35.4 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
ChromaDex Corporation ChromaDex Corporation
CDXC
- -0.88 % $ 598 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 101.39 -0.66 % $ 27.2 B germanyGermany
Checkpoint Therapeutics Checkpoint Therapeutics
CKPT
- - $ 169 M usaUSA
Avenue Therapeutics Avenue Therapeutics
ATXI
- -52.27 % $ 4.45 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Aquestive Therapeutics Aquestive Therapeutics
AQST
$ 4.06 -0.98 % $ 434 M usaUSA
Arcutis Biotherapeutics Arcutis Biotherapeutics
ARQT
$ 23.08 -1.45 % $ 2.94 B usaUSA
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.49 4.58 % $ 397 M britainBritain
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
AstraZeneca PLC AstraZeneca PLC
AZN
- - $ 96.9 B britainBritain
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.92 -0.14 % $ 4.81 M israelIsrael
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
bluebird bio bluebird bio
BLUE
- - $ 546 M usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
ContraFect Corporation ContraFect Corporation
CFRX
- -5.16 % $ 5.39 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.7 -1.45 % $ 114 M usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 1.06 -3.21 % $ 12.9 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 2.83 -2.92 % $ 284 M usaUSA